Emerald Bioscience Inc. (EMBI)
Stock Price:
$0.0400 USD
-0.0010 (-2.44%)
Updated Aug 7, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
7.33M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
13.48M |
| Shares Out |
183.21M |
| EPS (ttm) |
0.03 |
| PE Ratio |
1.33 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$0.0400 |
| Previous Close |
$0.0410 |
| Change ($) |
-0.0010 |
| Change (%) |
-2.44% |
| Day's Open |
0.0502 |
| Day's Range |
0.0410 - 0.0531 |
| Day's Volume |
923,544 |
| 52-Week Range |
0.0400 - 0.4900 |
More Stats
| Market Cap |
7.33M |
| Enterprise Value |
7.28M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
183.21M |
| Float |
52.34M |
| EPS (basic) |
0.11 |
| EPS (diluted) |
0.03 |
| FCF / Share |
-0.03 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
75.00% |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
0.84 |
| PE Ratio |
1.33 |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
30.09 |
| Revenue |
n/a |
| Operating Income |
-7.33M |
| Net Income |
13.48M |
| Free Cash Flow |
-5.86M |
| Net Cash |
50,622 |
| Net Cash / Share |
0.00 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-169.71% |
| ROE |
n/a |
| ROIC |
-294.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
2.00
Current: $0.0400
High
2.00
Target: 2.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | - | - | - | - | - | - | 0.02 |
| Gross Profit | - | - | - | - | - | - | - | 0.01 |
| Operating Income | -6.63 | -4.69 | -3.86 | -4.47 | -4.32 | -2.73 | -0.12 | - |
| Net Income | 1.05 | -19.19 | -3.09 | -3.18 | -4.84 | -2.73 | -0.12 | - |
| Shares Outstanding | 135 | 121 | 27.91 | 18.95 | 16.94 | 10.29 | 7.77 | 2.33 |
| Earnings Per Share | -0.05 | -0.16 | -0.11 | -0.17 | -0.29 | -0.27 | -0.02 | - |
| Operating Cash Flow | -6.03 | -3.94 | -3.33 | -3.55 | -3.73 | -1.76 | - | - |
| Capital Expenditures | - | - | -0.02 | -0.01 | - | -0.02 | - | - |
| Free Cash Flow | -6.03 | -3.95 | -3.35 | -3.56 | -3.73 | -1.78 | - | - |
| Cash & Equivalents | 1.83 | 1.86 | 0.26 | 0.10 | 3.26 | 0.21 | 0.00 | 0.03 |
| Total Debt | 0.39 | 1.36 | 0.24 | - | - | - | - | - |
| Net Cash / Debt | 1.45 | 0.50 | 0.03 | 0.10 | 3.26 | 0.21 | 0.00 | 0.03 |
| Assets | 2.00 | 1.96 | 0.56 | 0.32 | 3.51 | 0.35 | - | 0.04 |
| Liabilities | 1.45 | 17.52 | 1.36 | 1.77 | 3.04 | 0.80 | 0.18 | - |
| Book Value | 0.55 | -15.56 | -3.57 | -2.91 | -0.89 | -0.45 | -0.18 | 0.04 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Emerald Bioscience Inc. |
| Country |
United States |
| Employees |
4 |
| CEO |
Brian Stuart Murphy |
Stock Information
| Ticker Symbol |
EMBI |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: EMBI |
Description
Emerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111 for the treatment of glaucoma. Its products pipeline also comprise NB2222 for the treatment of dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3000 for the treatment of methicillin-resistant Staphylococcus aureus. The company was formerly known as Nemus Bioscience, Inc. and changed its name to Emerald Bioscience, Inc. in March 2019. Emerald Bioscience, Inc. was founded in 2012 and is headquartered in Long Beach, California.